Colorectal cancer (CRC) is the second most common newly diagnosed cancer and the second most common cause of death in the European Union (EU). CRC is an enormous health and economic burden. Early detection and prevention have the possibility of reducing this burden significantly. Many cancer-associated deaths can be avoided through early detection by high-quality colorectal screening programs followed by appropriate treatment. Under the auspices of the United European Gastroenterology Federation (UEGF), the European Association for Gastroenterology and Endoscopy, the Hungarian Society of Gastroenterology and the Hungarian College of Gastroenterology, the ‘Budapest Declaration’ (2011) was an accepted official scientific program during the Hungarian Presidency of the Council of the European Union. The Budapest Declaration follows the Munich Declaration (2001), the Brussels Declaration (2007), the Transatlantic Declaration (2009), the Barcelona Declaration (2010), the written declaration of CRC screening, a joint initiative with European Parliamentarians coordinated by the UEGF, and finally, the ‘European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis’. The ‘Budapest Declaration’ together with previous declarations aims to urge the national and supranational healthcare decision makers to launch new Europe-wide initiatives to establish high-quality CRC programs to achieve optimal efficiency in CRC screening. In case of implementation of the proposals, actions and conditions recommended, we can achieve that one of the basic principles of the EU – the chance of equal access – be realized in member states with respect to the prevention of CRC and reduction of cancer-related mortality. To better achieve this goal, we propose to establish an UEGF joint committee, with one participant representing each EU member state to coordinate and supervise the implementation of CRC screening.

1.
Ferlay J, Parkin DM, Steliarova-Fiocher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–781.
2.
O’Morain CA, Van Cutsem E, Spicak J, Classen M, Wood LF, Stockbrügger R: European initiatives in colorectal cancer screening. Eur J Gastroenterol Hepatol 2011;23:201–203.
3.
Pignone M, Saha S, Hoerger T, Mandelblatt J: Cost-effectiveness analysis of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002;137:96–104.
4.
Recommendations on cancer screening in the European Union: Advisory Committee on Cancer Prevention. Eur J Cancer 2000;36:1473–1478.
5.
Declarations of Munich (2001), Brussels (2007), Transatlantic Declaration, New York (2009). www.felix-burda-stiftung.de/declarations/.
6.
Castells A, Castellvi-Bel S, Balaguer F: Concepts in familial colorectal cancer: where do we stand and what is the future? Gastroenterology 2009;137:404–409.
7.
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al; UK Flexible Sigmoidoscopy Trial Investigators: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624–1633.
8.
European Commission; in Segnan N, Patrick J, von Karsa L (eds): European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, ed 1. Luxemburg, Publications Office of the European Union, 2010.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.